Is tirzepatide the same as Manjaro?

Is 'Manjaro' a different medicine, or just a typo?

It is a typo. Mounjaro is pronounced 'mown-JAR-oh', and the spelling trips people up constantly, a question our prescribers hear most weeks is some version of 'I've seen it spelled three different ways; are they all the same thing?' They are. Mounjaro, Manjaro and occasional variants like 'Monjaro' or 'Munjaro' all refer to the same UK-licensed product: a pre-filled KwikPen containing tirzepatide, manufactured by Eli Lilly.

Tirzepatide itself is the molecule. Mounjaro is its brand identity in the UK, much as paracetamol is the ingredient and Panadol is one brand name for it. When the NHS medicines page for tirzepatide uses the generic name, and a pharmacy uses the brand, they mean the same medicine. If you want to understand whether Manjaro and tirzepatide are genuinely the same thing, that page covers the relationship between the misspelled name and the active ingredient in full. If you've found a site selling something called 'Manjaro injectable' as though it were distinct from Mounjaro, treat that as a red flag, the MHRA has documented fake weight-loss pens circulating online, some containing entirely different substances.

For a closer look at how the brand and generic names relate, this page on tirzepatide and Mounjaro covers the relationship in more detail.

How does tirzepatide actually work inside the body?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are hormones the gut releases naturally after eating. They tell the pancreas to produce insulin, signal to the brain that food has arrived, and slow the rate at which the stomach empties. Tirzepatide mimics both signals at once, something no other UK-licensed weight-management injection currently does.

The practical effect is that appetite falls, meals feel more filling, and the impulse to eat between meals quietens. This isn't a willpower top-up; it is a physiological shift. The distinction between tirzepatide and a standard GLP-1 medicine matters if you're comparing it with semaglutide-based options, which act on only the GLP-1 pathway.

Tirzepatide comes in six UK strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg. The 2.5mg pen exists to let the body adjust before climbing the dose ladder, it is a settling-in dose, not the dose where most people see significant weight change. A prescriber oversees the whole titration. That staged approach is part of why clinical supervision matters, not just for the prescription itself but for the ongoing review that follows.

Who can be prescribed tirzepatide, and what does approval involve?

Under the licensed UK criteria, tirzepatide is approved for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Those are the licence thresholds; a prescriber may also consider other clinical factors, and UK guidance notes that lower BMI thresholds apply for certain ethnic backgrounds. Meeting the numbers on paper is a starting point, not a guarantee.

Tirzepatide is also licensed in the UK for type 2 diabetes management under a different clinical pathway, so if you see it discussed in a diabetes context, that is a separate indication, not weight management. For weight-related use specifically, our tirzepatide overview outlines what the treatment pathway looks like.

Cost is a real consideration for most people. Eli Lilly raised UK list prices in September 2025, and private prices now vary by dose and provider. For an honest breakdown of what affects the cost of a course of treatment, the Mounjaro pricing page goes through the detail without padding. NICE also recommends tirzepatide for eligible adults under technology appraisal TA1026, though NHS access is phased and not yet broadly available, private prescription remains the practical route for most people right now.

If you are unsure whether tirzepatide could be suitable for you, the right first step is a clinical consultation. At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it arrives. Check your eligibility by starting a free consultation, there is no commitment, and the clinical team will give you a straight answer.